Want to see ENGN full AI Analyst Report?
ENGN Stock Chart & Stats
$1.95
-$0.06(-3.30%)
At close: 4:00 PM EDT
$1.95
-$0.06(-3.30%)
Day’s Range― - ―
52-Week Range$1.40 - $12.25
Previous Close$1.74
Volume651.33K
Average Volume (3M)722.75K
Market Cap
$130.01M
Enterprise Value-$108.30M
Total Cash (Recent Filing)$266.32M
Total Debt (Recent Filing)$33.27M
Price to Earnings (P/E)―
Beta0.48
Next Earnings
Dec 23, 2026EPS Estimate
-0.46Next Dividend Ex-DateN/A
Dividend Yield3.5%
Share Statistics
EPS (TTM)-0.28
Shares Outstanding67,016,320
10 Day Avg. Volume853,886
30 Day Avg. Volume722,751
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)2.20
Price to Sales (P/S)0.00
P/FCF Ratio-3.66
Enterprise Value/Market Cap-0.83
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit197.99
Enterprise Value/Ebitda0.82
Forecast
1Y Price Target
$2.50Price Target Upside28.21% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)-1.81
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageThe very low debt burden gives enGene greater financial flexibility than many development-stage biotechnology companies. Limited leverage reduces fixed financing pressure and preserves the balance sheet’s ability to support clinical development, regulatory work, and potential commercialization activities.
Lead Therapy DifferentiationA localized, non-viral delivery approach may provide a differentiated treatment profile in bladder cancer by targeting the disease site directly. The platform’s focus on local immune activation could support product positioning and future expansion into additional localized genetic-medicine applications.
Clinical And Regulatory ProgressThe reported response data and progression toward pivotal readouts and a planned biologics filing indicate meaningful advancement of the lead program. These milestones can improve strategic options, support partnering discussions, and move the company closer to a potential commercial revenue base.
Bears Say
No Recurring RevenueWithout an approved commercial product, enGene lacks a recurring revenue stream to fund operations independently. Its future economics depend on successful development, regulatory approval, launch execution, or partnership income, making business outcomes highly dependent on milestones that remain ahead.
Sustained Cash BurnPersistent operating and free-cash-flow deficits require enGene to consume existing capital while advancing its pipeline. Continued burn can reduce financial flexibility over time and may increase dependence on financing, licensing, or other capital sources before a product generates meaningful cash.
Clinical And Regulatory UncertaintyEven with encouraging development signals, the lead program still faces approval, reimbursement, adoption, and commercial execution uncertainties. Any unfavorable outcome across these linked steps could delay commercialization, reduce the addressable opportunity, or require additional capital before revenue is achieved.
enGene Holdings News
ENGN FAQ
What was enGene Holdings’s price range in the past 12 months?
enGene Holdings lowest stock price was $1.40 and its highest was $12.25 in the past 12 months.
What is enGene Holdings’s market cap?
enGene Holdings’s market cap is $130.01M.
When is enGene Holdings’s upcoming earnings report date?
enGene Holdings’s upcoming earnings report date is Dec 23, 2026 which is in 79 days.
How were enGene Holdings’s earnings last quarter?
enGene Holdings released its earnings results on Sep 08, 2026. The company reported -$0.47 earnings per share for the quarter, missing the consensus estimate of -$0.427 by -$0.043.
Is enGene Holdings overvalued?
According to Wall Street analysts enGene Holdings’s price is currently Undervalued.
Does enGene Holdings pay dividends?
enGene Holdings pays a Quarterly dividend of $0.13 which represents an annual dividend yield of 3.5%. See more information on enGene Holdings dividends here
What is enGene Holdings’s EPS estimate?
enGene Holdings’s EPS estimate is -0.46.
How many shares outstanding does enGene Holdings have?
enGene Holdings has 67,016,320 shares outstanding.
What happened to enGene Holdings’s price movement after its last earnings report?
enGene Holdings reported an EPS of -$0.47 in its last earnings report, missing expectations of -$0.427. Following the earnings report the stock price went up 5.495%.
Which hedge fund is a major shareholder of enGene Holdings?
Currently, no hedge funds are holding shares in ENGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
enGene Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.50 (28.21% Upside)
$2.50 (28.21% Upside)
Blogger Sentiment
Bullish
ENGN Sentiment 100%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Decreased
By 1.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $10.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.8%
Last 30 Days ▼ 6.5%
Last 30 Days ▼ 6.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-76.16%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
17.42%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
enGene Holdings
Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after Bacillus Calmette-Guérin therapy. The company was established in 2023 and is headquartered in Saint-Laurent, Canada.
ENGN Stock 12 Month Forecast
Average Price Target
$2.50
▲(28.21% Upside)
Technical Analysis
Tvardi Therapeutics
―
Capricor Therapeutics
―
Replimune Group
―
Immuneering
―
Contineum Therapeutics, Inc. Class A
―
Ownership Overview
4.47% Insiders
0.73% Mutual Funds
44.49% Other Institutional Investors
50.31% Public Companies and
Individual Investors